Cargando…

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates

BACKGROUND: The incidence of organisms with extended-spectrum beta-lactamases (ESBLs) is increasing. The data for using cefepime in ESBL-producing Enterobacterales infections is conflicting. More favorable outcomes are likely if minimum inhibitory concentrations (MICs) < 2 mcg/mL. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia, Brandon, King, Madeline, Kludjian, Geena, Hanretty, Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752075/ http://dx.doi.org/10.1093/ofid/ofac492.699

Ejemplares similares

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas
por: Parker, Jennifer K, et al.
Publicado: (2023)

2789. Cefepime Versus Non-Cefepime/Non-Carbapenem Therapy for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Subgroup Analysis of The Carbapenem-Serratia Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023)

ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019
por: Bandy, Altaf, et al.
Publicado: (2021)

2136. In Vitro Activity of Nacubactam (OP0595) Combined with Cefepime against Carbapenem-resistant Enterobacterales Isolated in Japan
por: Yanagihara, Katsunori, et al.
Publicado: (2023)

2788. Cefepime or Carbapenem Definitive Therapy Versus Other Antibiotics for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland
por: Kuch, Alicja, et al.
Publicado: (2020)

Monitoring of Non-β-Lactam Antibiotic Resistance-Associated Genes in ESBL Producing Enterobacterales Isolates
por: Shinu, Pottathil, et al.
Publicado: (2020)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

Carbapenem-Sparing Strategies for ESBL Producers: When and How
por: Karaiskos, Ilias, et al.
Publicado: (2020)

Prevalence of ESBL, AmpC and Carbapenemase-Producing Enterobacterales Isolated from Raw Vegetables Retailed in Romania
por: Colosi, Ioana Alina, et al.
Publicado: (2020)

197. The Clinical Impact of Early Detection of ESBL-Producing Enterobacterales with PCR-Based Blood Culture Assays
por: Chang, Kai-Ming, et al.
Publicado: (2022)

2775. Clinical Outcomes and Treatment-Emergent Resistance of Piperacillin-tazobactam, Cefepime, Carbapenems and Fluoroquinolones for the Treatment of Bloodstream Infections due to AmpC β-Lactamase-Producing Enterobacterales
por: Jawanda, Jasanjeet, et al.
Publicado: (2023)

P081: Cefepime-tazobactam: a new antibiotic against ESBL producing enterobacteriaceae in cancer patients
por: Biswas, S, et al.
Publicado: (2013)

1199. Effectiveness of Non-carbapenem vs Carbapenems Empiric Therapy for Extended-Spectrum β-Lactamase (ESBL)-producing Enterobacterales (PE) Infections in Non-ICU patients: A Real-world Investigation in a Hospital with High-prevalence of ESBL-PE
por: Kang, Amy Y, et al.
Publicado: (2023)

Risk factors for predicting extended-spectrum β-lactamase-producing Enterobacterales (ESBLE) infections in non-urinary isolates
por: Burgoon, Rachel, et al.
Publicado: (2023)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing Enterobacterales and Differentiation of Carbapenem-Resistant Enterobacterales
por: Takei, Kentarou, et al.
Publicado: (2023)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021)

The Impact of COVID-19 Pandemic on ESBL-Producing Enterobacterales Infections: A Scoping Review
por: Mai, Ha Thi Thao, et al.
Publicado: (2023)

High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2023)

Antimicrobial susceptibility testing profiles of ESBL-producing Enterobacterales isolated from hospital and community adult patients in Blantyre, Malawi
por: Onduru, Onduru G., et al.
Publicado: (2021)

2150. In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
por: Wise, Mark G, et al.
Publicado: (2023)

Predominance of Non-carbapenemase Producing Carbapenem-Resistant Enterobacterales in South Texas
por: Black, Cody A., et al.
Publicado: (2021)

Epidemiology of carbapenem-resistant and carbapenemase-producing Enterobacterales in the Netherlands 2017–2019
por: Wielders, Cornelia C. H., et al.
Publicado: (2022)

Carriage of ESBL-producing Enterobacterales in wastewater treatment plant workers and surrounding residents — the AWARE Study
por: Rodríguez-Molina, Daloha, et al.
Publicado: (2021)

Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022)

Detection of Multidrug-Resistant Enterobacterales—From ESBLs to Carbapenemases
por: Noster, Janina, et al.
Publicado: (2021)

1053. The β-Lactamase Inhibitor QPX7728 Restores the Activity of β-Lactam Agents against Contemporary Extended-Spectrum β-lactamase (ESBL)-Producing and Carbapenem-Resistant Enterobacterales (CRE) Isolates, Including Isolates Producing Metallo-β-lactamases
por: Lindley, Jill, et al.
Publicado: (2021)

Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant Enterobacterales
por: Lim, Fang Kang, et al.
Publicado: (2020)

Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales
por: Ávila-Núñez, M., et al.
Publicado: (2023)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
por: Shortridge, Dee, et al.
Publicado: (2022)

The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment
por: Wu, Qian, et al.
Publicado: (2023)

CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales
por: Mathers, Amy J, et al.
Publicado: (2021)

1253. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance
por: Hackel, Meredith, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n0nsrhe2go2csqaac1qknli3ab